CD274 and cancer: Arthralgia and other musculoskeletal diseases attributed to anti-PD-L1 medication were more common among renal cell carcinoma patients than among individuals with other cancer types (20.0 %, 95 % CI 16.1%–24.3 %; 23.6 %, 95 % CI 19.5%–28.1 %, respectively).